For the first time in a decade, obesity in the U.S. is declining — and a new study suggests it’s because of wildly popular ...

Despite this escalating demand for popular GLP-1 drugs, the prices for some of these products are actually dropping. Dr.

A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such ...

One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...

Despite the skepticism and outrage over Robert F. Kennedy Jr.’s nomination to head the Department of Health and Human ...

Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug ...

They are currently approved for treating diabetes, obesity and those with a history of cardiovascular disease in people who ...

Eli Lilly is partnering with the Flatiron-based telehealth company Ro to sell a cheaper version of its popular weight-loss ...

Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk.

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...